Evidence map›Paper›PMID 42027593›Full record

ArticleBone reports2026

Early intermittent low-dose sclerostin antibody treatment promotes surface bone formation and reduces bone loss, but also decreases osteocyte apoptosis and mechanotransduction in ovariectomized rats: A pilot study.

Syeda Masooma Naqvi, Wahaaj Ali, Hollie Allison, Laura M O'Sullivan, Gill Holdsworth, Juan Alberto Panadero-Perez, Jessica Schiavi-Tritz, Laoise M McNamara

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Syeda Masooma NaqviMechanobiology and Medical Devices Research Group (MMDRG), Biomedical Engineering, University of Galway, Ireland.
Wahaaj AliMechanobiology and Medical Devices Research Group (MMDRG), Biomedical Engineering, University of Galway, Ireland.
Hollie AllisonMechanobiology and Medical Devices Research Group (MMDRG), Biomedical Engineering, University of Galway, Ireland.
Laura M O'SullivanMechanobiology and Medical Devices Research Group (MMDRG), Biomedical Engineering, University of Galway, Ireland.
Gill HoldsworthEarly Solutions, UCB Pharma, Slough, UK.
Juan Alberto Panadero-PerezMechanobiology and Medical Devices Research Group (MMDRG), Biomedical Engineering, University of Galway, Ireland.
Jessica Schiavi-TritzMechanobiology and Medical Devices Research Group (MMDRG), Biomedical Engineering, University of Galway, Ireland.
Laoise M McNamaraMechanobiology and Medical Devices Research Group (MMDRG), Biomedical Engineering, University of Galway, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neutralizing sclerostin antibodies (Scl-Ab) mitigate bone loss and promote bone formation to address fracture risk in postmenopausal osteoporosis. Clinically, this treatment is administered monthly for women at high risk of fragility fractures, who are often years into menopause. Preclinical studies have demonstrated that dampening of bone formation occurs with continuous dosing at supraphysiological doses. Osteoporotic bone loss occurs rapidly during early menopause, followed by longer-term changes in bone mineralization and osteocyte activity. Whether earlier administration of lower-exposure Scl-Ab can mitigate bone loss and osteocyte-mediated mineralization is unknown. The objective of this study was to evaluate the effects of early intermittent low-dose Scl-Ab on: (1) osteoclastogenesis and bone resorption, (2) perilacunar remodelling, (3) secondary mineralization, and (4) osteocyte mechanosensitivity. Female retired breeder Wistar rats underwent bilateral ovariectomy and received monthly low-dose Scl-Ab injections (2 mg/kg/month) from 3 to 14 weeks post-OVX, while a control group remained untreated. Early intermittent low-dose Scl-Ab treatment increased bone formation and reduced osteoclastogenesis and catabolic gene expression ((Sost, Ctsk, Mmp9) compared to untreated rats. Treatment also decreased the percentage of empty lacunae and the number of MMP14+ osteocytes, accompanied by lower perilacunar mineral density and smaller lacunar size, indicating improved osteocyte survival and reduced perilacunar remodelling. Conversely, expression of osteocyte-mediated mineralization genes (DMP1, PHEX, OPN, ALP) and mechanotransduction-related genes (Vcl, integrins α5, αV, β1, CX43, Axin2, IFT88, Adcy6, Pkd1, Cav1) were reduced. Together, these findings suggest that early intermittent low-dose Scl-Ab therapy promotes surface bone formation while attenuating osteocyte-mediated mineralization after initial bone loss.

Indexed as

Bone remodellingEarly interventionOvariectomized ratsPostmenopausal osteoporosisSclerostin antibody (Scl-Ab)Secondary mineralization

Identifiers

PMID42027593
PMCPMC13101557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.